TOI ONCOLOGY INSTITUTE INC (THE)

The Oncology Institute Partners with House Rx to Accelerate Growth of Pharmacy Operations

The Oncology Institute Partners with House Rx to Accelerate Growth of Pharmacy Operations

Collaborative efforts aimed at expanding TOI's current specialty medication services

SAN FRANCISCO, July 31, 2023 (GLOBE NEWSWIRE) -- (NASDAQ: TOI) and House Rx announced today that they have entered into a multi-year relationship that will integrate House Rx’s specialty medication dispensing model to operate and manage TOI’s clinic and pharmacy locations in multiple markets.

House Rx provides clinics with specialized technology and services support from pharmacists and care coordinators. House Rx staff are integrated with the clinic to help patients start therapy as quickly as possible and drive adherence to treatment for better outcomes.

TOI’s alignment with House Rx will expand patient access to oral specialty medications via TOI dispensary and pharmacy locations, and enhance in-office dispensary operations. The relationship will further enable TOI to provide convenient and affordable access to value-based therapies for patients as part of its comprehensive community-based care model.

“By partnering with House Rx, we will accelerate the growth of our clinic-based oral drug dispensing capabilities and improve our ability to add pharmacy locations in California and Texas that will allow us to access patient populations that we previously could not serve,” said Dr. Daniel Virnich, CEO of The Oncology Institute. “We see this as one of the key drivers of our growth in upcoming years.”

"With TOI, we have an innovative partner that cares deeply about delivering value-based care in the community setting," said Tesh Khullar, President and Co-Founder of House Rx. "By adopting our dispensing services and technology, TOI will strengthen their value-based care offering by ensuring more patients can access their specialty medications and receive the best possible outcomes from their treatments.”

About The Oncology Institute, Inc.

Founded in 2007, TOI is advancing oncology by delivering highly specialized, value-based cancer care in the community setting. TOI offers cutting-edge, evidence-based cancer care to a population of approximately 1.8 million patients including clinical trials, transfusions, and other care delivery models traditionally associated with the most advanced care delivery organizations. With 100+ employed clinicians and more than 800 teammates in over 65 clinic locations and growing, TOI is changing oncology for the better. For more information visit .

About House Rx

House Rx is a healthcare technology and services company focused on making specialty medication more accessible and affordable. The company partners with specialty clinics across the country to enable community-based clinics to offer medically integrated dispensing, ultimately bringing together medical and pharmacy expertise to better serve patients, lower the cost of care, and create a better experience for patients and their caregivers. Learn more at .

Investors

Solebury Strategic Communications



EN
31/07/2023

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on ONCOLOGY INSTITUTE INC (THE)

 PRESS RELEASE

The Oncology Institute and SilverSummit Healthplan Partner to Provide ...

The Oncology Institute and SilverSummit Healthplan Partner to Provide Oncology Care to Over 80,000 Medicaid Members in Nevada CERRITOS, Calif., June 30, 2025 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (NASDAQ: TOI) (“TOI”), one of the largest value-based oncology groups in the United States, announced today that effective July 1, it will be the exclusive oncology provider for over 80,000 Medicaid patients associated with SilverSummit Healthplan in Nevada. TOI is known for bringing state-of-the-art cancer care to the communities it serves, and their presence in the Las Vegas market w...

 PRESS RELEASE

The Oncology Institute set to join the Russell 2000® and Russell 3000®...

The Oncology Institute set to join the Russell 2000® and Russell 3000® Indexes CERRITOS, Calif., June 03, 2025 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (NASDAQ: TOI) (“TOI”), one of the largest value-based oncology groups in the United States, today announced that it will join the Russell 2000® and Russell 3000® after the 2025 Russell indexes annual reconstitution, effective after the US market closes on June 27, according to a preliminary list of additions posted on May 23. Annual Russell indexes reconstitution captures the 4,000 largest US stocks as of April 30, ranking them by...

 PRESS RELEASE

The Oncology Institute Reports First Quarter 2025 Financial Results an...

The Oncology Institute Reports First Quarter 2025 Financial Results and Reaffirms Full Year 2025 Guidance CERRITOS, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (NASDAQ: TOI) (“TOI” or the “Company”), one of the largest value-based community oncology groups in the United States, today reported financial results for its three months ended March 31, 2025. Recent Operational Highlights Retail Pharmacy and Dispensary set fill records, contributing $49.3 million revenue and over $9 million in gross profit in Q1. The Pharmacy and Dispensary segment grew over 20% in th...

 PRESS RELEASE

The Oncology Institute Welcomes Dr. Jeff Langsam as Chief Clinical Off...

The Oncology Institute Welcomes Dr. Jeff Langsam as Chief Clinical Officer CERRITOS, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (NASDAQ: TOI) (“TOI”), one of the largest value-based oncology groups in the United States, announced today that Dr. Jeffrey Langsam will assume the role of enterprise Chief Clinical Officer effective May 13th, 2025. The CCO role will oversee therapeutics including pathway and procurement decisions, utilization management, and MSO practice clinical engagement. Dr. Langsam joins TOI from Cigna Healthcare, where he was the National Direct...

 PRESS RELEASE

The Oncology Institute to Participate at the B. Riley Securities 25th ...

The Oncology Institute to Participate at the B. Riley Securities 25th Annual Institutional Investor Conference CERRITOS, Calif., May 13, 2025 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (NASDAQ: TOI) (“TOI”), one of the largest value-based oncology groups in the United States, today announced that Dr. Daniel Virnich, Chief Executive Officer, and Rob Carter, Chief Financial Officer, will participate in B. Riley’s 25th Annual Institutional Investor Conference in Marina Del Rey, CA on May 21st, 2025. About The Oncology Institute Founded in 2007, TOI is advancing oncology by delivering...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch